Products
Since its inception, APTYS has proposed developments on proprietary technologies with a focus on the final product. Among those technologies, Adhapt® and Bi-Gel are currently marketed and evaluated in Clinical Phase III respectively. We pursue this goal in the development of our internal research programs.